Every material Form 8-K Syndax Pharmaceuticals Inc has filed with the SEC since July 14, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Syndax reported third-quarter 2026 total revenue of $83.3 million, up from $45.9 million a year earlier, and a net loss of $49.4 million, or $0.55 per share, versus $60.7 million, or $0.70 per share, in the prior-year quarter. The company also said its Chief Financial Officer, Keith Goldan, will retire effective November 9, 2026, and Aaron A. Ondrey will succeed him on the same date.
Revuforj net revenue was $60.7 million in Q3 2026, up 90% year over year; Niktimvo collaboration revenue to Syndax was $22.6 million.
Q3 2026 research and development expenses rose to $67.5 million from $56.3 million; SG&A fell to $43.7 million from $44.9 million.
Company continues to expect 2026 R&D plus SG&A expenses of about $400 million, excluding about $50 million of estimated non-cash stock compensation.
Ondrey joins as CFO effective November 9, 2026, with a $543,000 base salary and a 45% target bonus; Goldan will continue as an advisor for an interim period.
Syndax Pharmaceuticals reported second-quarter 2026 total revenue of $72.8 million, up 92% from a year earlier, driven by $54.7 million in Revuforj net revenue and $18.1 million in Niktimvo collaboration revenue. The quarterly net loss narrowed to $49.4 million, or $0.55 per share, from $71.8 million, or $0.83 per share, a year earlier, and the company continues to expect 2026 research and development plus selling, general and administrative expenses of about $400 million, excluding about $50 million of non-cash stock compensation.
Total revenue of $72.8 million in Q2 2026 versus $38.0 million in Q2 2025.
Revuforj net revenue of $54.7 million, up 91% year over year; Niktimvo net revenue of $60.3 million, with Syndax's collaboration revenue at $18.1 million.
Quarterly net loss of $49.4 million, or $0.55 per share, compared with $71.8 million, or $0.83 per share, in Q2 2025.
Cash, cash equivalents and investments were $575.1 million as of June 30, 2026; Phase 2 axatilimab topline data in IPF and frontline cGVHD are expected in Q4 2026.
Syndax Pharmaceuticals held an R&D event on July 14, 2026, and disclosed two pipeline additions: SNDX-4321, an externally licensed EGFR inhibitor for non-small cell lung cancer, and SNDX-62122, a next-generation menin inhibitor selected for myelofibrosis. The filing furnishes the press release and presentation but gives no new financial results, and it sets out development timelines, including a Phase 2 axatilimab trial in IPF with topline data expected in 4Q26.
SNDX-4321: IND submission expected by end of 2026 and Phase 1 trial in EGFR-mutated NSCLC planned for 2027; Syndax holds an exclusive worldwide license.
SNDX-62122 is the first candidate from Syndax's wholly owned next-generation menin inhibitor library; a revumenib Phase 1/2 proof-of-principle trial in myelofibrosis is expected to start in 4Q26.
Phase 2 trial of axatilimab in IPF remains on track for topline data in 4Q26.
Presentation states Revuforj and Niktimvo were each annualizing at about $200 million as of 1Q26.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Syndax Pharmaceuticals Inc filing is on SEC EDGAR ↗. 8-K briefs of other companies →